Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 12:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 3,713 matching trials from the live ClinicalTrials.gov search.
Conditions
Type II Diabetes
Interventions
Farxiga, Placebo, Metformin, Insulin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • Huntington Park, California + 23 more
Conditions
Type 2 Diabetes, Overweight and Obese Adults
Interventions
Low-fat, vegan diet
Behavioral
Lead sponsor
Physicians Committee for Responsible Medicine
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Completed Not applicable Interventional Results available

Home Exercise to Enhance Mobility for Older Diabetics

NCT01308008
Conditions
Diabetes Mellitus Type 2
Interventions
home exercise/physical activity (PA) enhancement program with behavioral support, flex and toning health education program
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Type 2 Diabetes, Cardiovascular Risk
Interventions
Zenagamtide, Insulin glargine U-100
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
45 Years and older
Enrollment
1,778 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
109
States / cities
Birmingham, Alabama • Fairhope, Alabama • Montgomery, Alabama + 91 more
Conditions
Spinal Cord Injuries, Type 2 Diabetes
Interventions
Semaglutide Injectable Product, Placebo
Drug · Other
Lead sponsor
Marzieh Salehi
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
San Antonio, Texas
Conditions
Type 2 Diabetes, Hypertension, Obesity and Obesity-related Medical Conditions, Heart Disease
Interventions
Nutrition Matters
Behavioral
Lead sponsor
Winston Salem State University
Other
Eligibility
35 Years to 64 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Type 2 Diabetes
Interventions
Insulin glargine/lixisenatide Fixed Ratio Combination, Insulin glargine (HOE901), Lixisenatide (AVE0010), Metformin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
1,170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
118
States / cities
Phoenix, Arizona • Tempe, Arizona • Little Rock, Arkansas + 98 more
Conditions
Type II Diabetes Mellitus
Interventions
MI- informed SMS program
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 90 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Type 2 Diabetes
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
17 Years to 66 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Type2 Diabetes, Disability Physical
Interventions
Motor-assisted cycling, FES cycling
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
60 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Chandler, Arizona
Conditions
Diabetes Mellitus, Type 2
Interventions
IcoSema, Insulin icodec
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
110
States / cities
Gilbert, Arizona • Glendale, Arizona • Phoenix, Arizona + 90 more
Completed Not applicable Interventional Accepts healthy volunteers

Foundations for Health

NCT01304615
Conditions
Overweight, Obese
Interventions
Decrease Energy Density of the Diet, Increase Steps per Day, Consumption of Self-made Meals
Behavioral
Lead sponsor
The University of Tennessee, Knoxville
Other
Eligibility
18 Years to 35 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Knoxville, Tennessee
Conditions
Type 2 Diabetes
Interventions
Long-acting bedtime insulin detemir (Levemir), Insulin detemir and pre-meal insulin aspart.
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Completed Not applicable Interventional Results available

Control-IQ Technology in Individuals With Type 2 Diabetes

NCT05111301
Conditions
Type 2 Diabetes Treated With Insulin
Interventions
Control-IQ technology 1.5
Device
Lead sponsor
Tandem Diabetes Care, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Rochester, Minnesota • New York, New York • Austin, Texas
Conditions
Heart Failure, Type 2 Diabetes
Interventions
aerobic exercise training
Behavioral
Lead sponsor
Duke University
Other
Eligibility
50 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Diabetes Mellitus, Type 2
Interventions
Dapagliflozin, Exenatide, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Terminated Phase 1 Interventional Accepts healthy volunteers

A Multiple Dose Study Of PF-05161704 In Healthy Volunteers

NCT01202266
Conditions
Diabetes Mellitus, Type 2
Interventions
PF-05161704 or Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
New Haven, Connecticut
Completed No phase listed Observational Accepts healthy volunteers

Adiponectin and Ethnic Differences in Insulin Resistance

NCT01831102
Conditions
Insulin Resistance, Type 2 Diabetes
Interventions
none- observational study
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 60 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Placebo, Metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
915 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
28
States / cities
Tempe, Arizona • Encino, California • Fresno, California + 24 more
Conditions
Type 1 Diabetes Mellitus, Glucokinase-Maturity Onset Diabetes of the Young (GCK-MODY), MODY2 Diabetes, Healthy Volunteer
Interventions
Study Visit 1, Placebo, Study Visit 2, Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor
Procedure · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Diabetes Mellitus Type 2
Interventions
GK Activator (2), Simvastatin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
San Antonio, Texas • Tacoma, Washington
Completed Phase 2Phase 3 Interventional Results available

A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes

NCT00357370
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
16
States / cities
Jonesboro, Arkansas • Fresno, California • Greenbrae, California + 13 more
Conditions
Diabetes Mellitus, Type 2
Interventions
vildagliptin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
639 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
East Hanover, New Jersey
Conditions
Type 2 Diabetes Mellitus
Interventions
Bionic Pancreas, Usual Care
Device · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts